Peanut Oral Immunotherapy in Children (IMPACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01867671|
Recruitment Status : Completed
First Posted : June 4, 2013
Results First Posted : January 22, 2020
Last Update Posted : March 16, 2020
|Condition or disease||Intervention/treatment||Phase|
|Peanut Hypersensitivity||Biological: Peanut Oral Immunotherapy - Liquid Extract Biological: Placebo for Peanut Oral Immunotherapy - Liquid Extract form Biological: Peanut Oral Immunotherapy - Peanut Flour Biological: Placebo for Peanut Oral Immunotherapy - Peanut Flour||Phase 2|
An initial oral food challenge (OFC) to 1 g of peanut flour (500 mg peanut protein) will be conducted. Participants must have a clinical reaction during this OFC to initiate study dosing. After the initial OFC, the study design includes four phases:
- Initial dose escalation (1 day): Peanut or placebo dosing will be given incrementally and increase every 20 minutes until a dose of 12 mg peanut flour (6 mg peanut protein) or placebo flour is given.
- Build-up (30 weeks): Initial observed dose administration of highest tolerated dose, followed by daily OIT at home with return visit every 2 weeks for dose escalation.
- Maintenance (104 weeks):The participant will continue on daily OIT with return visits every 13 weeks. At the end of this phase the participant will undergo a blinded OFC to 10 g peanut flour (5 g peanut protein).
- Avoidance (26 weeks): In this final phase participants will be seen every 13 weeks. At the completion of this phase participants will have a final blinded OFC to 10g peanut flour (5 g peanut protein).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||146 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children (ITN050AD)|
|Actual Study Start Date :||August 13, 2013|
|Actual Primary Completion Date :||July 2, 2018|
|Actual Study Completion Date :||December 21, 2018|
Experimental: Peanut Oral Immune Therapy (OIT)
Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.
Biological: Peanut Oral Immunotherapy - Liquid Extract
Used during initial dose escalation for doses 0.1 to 0.8 mg.
Biological: Peanut Oral Immunotherapy - Peanut Flour
This will be used for the remainder of dose escalation, build-up, and maintenance.
Placebo Comparator: Peanut Placebo
Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks. The placebo extract will be derived from oat flour source material.
Biological: Placebo for Peanut Oral Immunotherapy - Liquid Extract form
Similar in appearance, texture, and taste to peanut liquid extract.
Biological: Placebo for Peanut Oral Immunotherapy - Peanut Flour
Similar in appearance, texture, and taste to peanut flour.
- Percentage of Participants Desensitized to Peanut Protein After 134 Weeks of Oral Immunotherapy (OIT) [ Time Frame: Week 134 ]
Definition of desensitized to peanut: A participant who passed the blinded (masked) oral food challenge (OFC) to10 grams of peanut flour (=5 grams of peanut protein) without significant symptoms.*
*Significant symptoms include hives, wheezing, vomiting, or laryngeal edema.
- Percentage of Tolerant Participants at Week 160 [ Time Frame: Week 160 ]Definition of Tolerant: A participant who passed the oral food challenge (OFC) to 10 grams of peanut flour (=5 grams of peanut protein).
- Count of Participants With Transient Desensitization [ Time Frame: Week 134, Week 160 ]Definition of transient desensitization: A participant who passed the blinded (masked) oral food challenge (OFC) to 10 grams peanut flour (=5 grams peanut protein) at week 134 and failed the week 160 in the Peanut oral immunotherapy (OIT) group.
- Highest Tolerated Cumulative Dose [ Time Frame: Week 160 ]
The highest tolerated cumulative dose of peanut protein during the blinded (masked) oral food challenge (OFC) at Week 160, analyzed within and between both placebo and peanut OIT groups. The highest cumulative dose of peanut protein tolerated for each participant was analyzed as a continuous outcome.
Any randomized participant without an evaluable blinded (masked) OFC was imputed as not tolerant. For the continuous highest cumulative dose endpoint, this is defined as having a highest cumulative dose imputed as zero.
- Percentage of Participants That Withdrew From the Study [ Time Frame: Initial Dose Escalation through Week 160 (Tolerance Assessment) ]Percentage of participants that withdrew from study participation, listed by study phase (at time of study withdrawal).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01867671
|United States, Arkansas|
|University of Arkansas for Medical Sciences: Arkansas Children's Hospital|
|Little Rock, Arkansas, United States, 72202|
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94040|
|United States, Maryland|
|Johns Hopkins Hospital|
|Baltimore, Maryland, United States, 21287|
|United States, New York|
|Mount Sinai School of Medicine|
|New York, New York, United States, 10029|
|United States, North Carolina|
|Chapel Hill, North Carolina, United States, 27599|
|Study Chair:||Wesley Burks, MD||UNC Chapel-Hill|
|Study Chair:||Stacie M. Jones, MD||University of Arkansas|